Compare LOB & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | NBTX |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2014 | 2018 |
| Metric | LOB | NBTX |
|---|---|---|
| Price | $40.76 | $35.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $43.00 | $36.00 |
| AVG Volume (30 Days) | ★ 253.8K | 55.9K |
| Earning Date | 04-22-2026 | 03-31-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.52 | $58.17 |
| Revenue Next Year | $16.03 | N/A |
| P/E Ratio | $68.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.36 | $4.57 |
| 52 Week High | $42.89 | $57.14 |
| Indicator | LOB | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.86 | 46.28 |
| Support Level | $39.43 | $30.15 |
| Resistance Level | $42.72 | $38.29 |
| Average True Range (ATR) | 0.99 | 2.68 |
| MACD | 0.25 | -0.03 |
| Stochastic Oscillator | 85.08 | 60.06 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.